Cavernous angioma future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:


*Several insights on development of cavernous angioma exist.
*Several insights on development of cavernous angioma exist.
*factors other than genetic mutation are considered such as: <ref name="pmid23506982">{{cite journal| author=Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Tournier-Lasserve E| title=Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis. | journal=Trends Mol Med | year= 2013 | volume= 19 | issue= 5 | pages= 302-8 | pmid=23506982 | doi=10.1016/j.molmed.2013.02.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23506982  }} </ref><ref name="pmid27639680">{{cite journal| author=Retta SF, Glading AJ| title=Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin. | journal=Int J Biochem Cell Biol | year= 2016 | volume= 81 | issue= Pt B | pages= 254-270 | pmid=27639680 | doi=10.1016/j.biocel.2016.09.011 | pmc=5155701 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27639680  }} </ref>
*Factors other than genetic mutation are considered such as: <ref name="pmid23506982">{{cite journal| author=Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Tournier-Lasserve E| title=Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis. | journal=Trends Mol Med | year= 2013 | volume= 19 | issue= 5 | pages= 302-8 | pmid=23506982 | doi=10.1016/j.molmed.2013.02.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23506982  }} </ref><ref name="pmid27639680">{{cite journal| author=Retta SF, Glading AJ| title=Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin. | journal=Int J Biochem Cell Biol | year= 2016 | volume= 81 | issue= Pt B | pages= 254-270 | pmid=27639680 | doi=10.1016/j.biocel.2016.09.011 | pmc=5155701 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27639680  }} </ref>
**oxidative stress
**oxidative stress
**inflammation
**inflammation

Revision as of 07:14, 26 February 2022

Cavernous angioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cavernous angioma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

CT

MRI

MRA

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cavernous angioma future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cavernous angioma future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cavernous angioma future or investigational therapies

CDC on Cavernous angioma future or investigational therapies

Cavernous angioma future or investigational therapies in the news

Blogs on Cavernous angioma future or investigational therapies

Directions to Hospitals Treating Cavernous angioma

Risk calculators and risk factors for Cavernous angioma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorrraine F. Co, D.M.D., M.D.

Future Investigations

  • Several insights on development of cavernous angioma exist.
  • Factors other than genetic mutation are considered such as: [1][2]
    • oxidative stress
    • inflammation
    • alterations in angiogenesis
    • gut microbiome involvement
      • lipopolysaccharide can stimulate the toll-like receptor 4 (TLR4) found on walls of endothelium [3]

References

  1. Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Tournier-Lasserve E (2013). "Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis". Trends Mol Med. 19 (5): 302–8. doi:10.1016/j.molmed.2013.02.004. PMID 23506982.
  2. Retta SF, Glading AJ (2016). "Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin". Int J Biochem Cell Biol. 81 (Pt B): 254–270. doi:10.1016/j.biocel.2016.09.011. PMC 5155701. PMID 27639680.
  3. Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N; et al. (2017). "Endothelial TLR4 and the microbiome drive cerebral cavernous malformations". Nature. 545 (7654): 305–310. doi:10.1038/nature22075. PMC 5757866. PMID 28489816.